Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
2(50.0%)
4Total
Phase 2(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03804229Phase 3Active Not Recruiting

Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia

Role: collaborator

NCT04675450Phase 2Withdrawn

NBP in Women With Metastatic Breast Cancer to Prevent Nab-paclitaxel Induced Toxic Neuropathy

Role: collaborator

NCT05757635Unknown

A Research of Application of the New Model of Standardized Secondary Prevention of Stroke

Role: collaborator

NCT02905565Phase 2Completed

NBP in Adult Patients With Acute Ischemic Stroke (AIS)

Role: lead

NCT01405248Phase 3Completed

Butylphthalide for Preventing Restenosis After Intracranial and Extracranial Artery Stenting

Role: collaborator

All 5 trials loaded